Skip to main content
. 2019 Sep 30;51(10):114. doi: 10.1038/s12276-019-0315-2

Fig. 6. DCA induces hepatic Fgf21 mRNA expression partially through PPARα and AMPK.

Fig. 6

a The effect of 15 min of pretreatment with the PPARα antagonist GW6471 (10 µM) on Fgf21 mRNA expression. b Fgf21 mRNA expression level in WT or PPARα−/− mouse primary hepatocytes after DCA (1 mM) treatment for 3 h. c Pparα mRNA expression in the liver of fed and fasted animals after DCA (100 mg/kg) administration for 1 week. d Pparα mRNA expression in mouse primary hepatocytes after DCA (1 mM) treatment for the indicated time (n = 3). e Phosphorylated AMPK expression in primary hepatocytes after DCA treatment as the indicated dose for the indicated time. Two different whole-blot images are shown in Supplementary Fig. 4. f The effect of 30 min of pretreatment with the AMPK inhibitor compound C (10 µM) prior to DCA (1 mM) treatment for 3 h on Fgf21 mRNA expression. The values are expressed as the mean ± SD (a–c, e and f) or ± SEM (c). Statistical analysis was determined by Student’s t test. *p < 0.05 vs. the control group, †p < 0.05 vs. the DCA-treated group. The vehicle control was a 0.1% DMSO solution